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408Communicating the Promise for Ocular Gene
Therapies: Challenges and RecommendationsSHELLY BENJAMINY, STEPHANIE P. KOWAL, IAN M. MACDONALD, AND TANIA BUBELA PURPOSE: To identify challenges and pose solutions
for communications about ocular gene therapy between
patients and clinicians as clinical research progresses.
 DESIGN: Literature review with recommendations.
 METHODS: Literature review of science communica-
tion best practices to inform recommendations for
patient-clinician discussions about ocular gene therapy.
 RESULTS: Clinicians need to employ communications
about ocular gene therapy that are both attentive to
patient priorities and concerns and responsive to other
sources of information, including overly positive news
media and the Internet. Coverage often conflates
research with therapy—clinical trials are experimental
and are not risk free. If proven safe and efficacious,
gene therapy may present a treatment but not a cure
for patients who have already experienced vision loss.
Clinicians can assist patients by providing realistic esti-
mates for lengthy clinical development timelines and
positioning current research within models of clinical
translation. This enables patients to weigh future thera-
peutic options when making current disease manage-
ment decisions.
 CONCLUSIONS: Ocular gene therapy clinical trials
are raising hopes for treating a myriad of hereditary
retinopathies, but most such therapies are many years
in the future. Clinicians should be prepared to counter
overly positive messaging, found in news media and on
the Internet, with optimism tempered by evidence to
support the ethical translation of gene therapy and
other novel biotherapeutics. (Am J Ophthalmol
2015;160(3):408–415.  2015 The Authors.
Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
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 2015 THE AUTHORS. PUBR
ECENT SUCCESSES IN OCULAR GENE THERAPY CLIN-
ical trials have revitalized hopes for a field that was
previously marked by high-profile disappoint-
ments.1 Pioneering clinical trials to address mutations of
the RPE65 gene that cause Leber congenital amaurosis
(LCA) established safety and demonstrated improvements
in visual function.2–4 These studies were celebrated by the
research community and the media,5 igniting hopes for
gene therapies for related retinopathies. Our goal here is
to identify challenges and pose solutions for communica-
tions about ocular gene therapy between patients and clini-
cians as clinical research progresses. Although we focus on
gene therapy, similar considerations apply to other experi-
mental biotherapeutics.
The discussion is timely. One research group at the
University of Pennsylvania reports that positive safety
and efficacy results from the LCA trials have been sustained
over time in adults and children6; readministration in the
second eye of 3 adult patients was both safe and efficacious
after previous exposure to the vector.6 A fully enrolled
phase III pediatric clinical trial is underway and expected
to report in late 2015 (NCT00999609). The pediatric trial
is crucial because LCA studies suggest a therapeutic win-
dow for visual gain, with earlier application leading to
more dramatic responses.7
Although these results appear promising, studies in
dogs suggest that degenerative processes may continue
after the gene therapy intervention, if such degeneration
has already commenced.8 In humans, a second research
group reported that gene therapy improves vision for at
least 3 years, but photoreceptor degeneration also con-
tinues at the same rate as in the natural course of the dis-
ease.9 Long-term follow-up (4.5-6 years) from 3 treated
patients indicated progressive diminution of the areas
of improved vision.10 Similar results were reported by a
team from the United Kingdom: retinal sensitivity
improved after gene therapy but diminished after
12 months.11 Gene therapy may therefore not offer a
permanent treatment, and most benefit is likely if the
intervention occurs prior to the onset of retinal degener-
ation.8 Some patients may require a second round of gene
therapy, and gene therapy may best be used in combina-
tion with other medications, if and when these are devel-
oped.12 Research continues to improve gene therapy0002-9394
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TABLE. Completed or Active Ocular Gene Therapy Clinical Trials Registered in ClinicalTrials.gov by May 2015 and Associated PUBMED Publications
Disease Intervention Phase Enrollment Age Group Start Year - End Year Status Sponsor Clinical Trial Identifier
Choroideremia AAV2-hCHM I/II 10 A,S 2015–2021 R Spark Therapeuticsa NCT02341807
rAAV2 REP1b II 30 A,S 2015–2018 NYR University of Oxford NCT02407678
rAAV2.REP1b I/II 12 A,S 2011–2015 R University of Oxford NCT01461213c
rAAV2.REP1b I 6 A,S 2015–2018 R University of Alberta NCT02077361
Leber congenital amaurosis AAV2-hRPE65v2 III 24 C,A,S 2012–2029 ONR Spark Therapeuticsa NCT00999609
AAV2-hRPE65v2 I/II 12 C,A,S 2010–2026 ONR Spark Therapeuticsa NCT01208389
AAV2-hRPE65v2 I 12 C,A,S 2007–2024 ONR Spark Therapeuticsa NCT00516477d
rAAV2-CB-hRPE65 I/II 12 C,A,S 2008–2027 ONR Applied Genetic Technologiesa NCT00749957
rAAV 2/2.hRPE65p.hRPE65 I/II 12 C,A 2007–N/A ONR University College, London NCT00643747e
rAAV2-CBSB-hRPE65 I 15 C,A,S 2007–2026 ONR University of Pennsylvania NCT00481546f
rAAV2/4.hRPE65 I/II 9 C,A 2011–2014 Com Nantes University Hospital NCT01496040
rAAV2-hRPE65 I 10 C,A,S 2010–2017 R Hadassah Medical Organization NCT00821340
Leber hereditary optic neuropathy scAAV2-P1ND4v2 I 27 A 2014–2019 R John Guy, University of Miami NCT02161380
rAAV2-ND4 N/A 6 C,A 2011–2013 R Bin Li, Huazhong University of Science
and Technology
NCT01267422
Neovascular age-related macular
degeneration
rAAV.sFlt-1 I/II 40 A,S 2011–2015 ONR Lions Eye Institute, Australia NCT01494805
AAV2-sFLT01 I 34 A,S 2010–2018 ONR Genzyme, a Sanofi Coa NCT01024998
RetinoStat I 21 A,S 2011–2015 ONR Oxford BioMedicaa NCT01301443
RetinoStat I 21 A,S 2012–2027 R Oxford BioMedicaa NCT01678872
AdGVPEDF.11D I N/A A,S N/A Com GenVeca NCT00109499
Retinitis pigmentosa rAAV2-VMD2-hMERTK I 6 C,A,S 2011–2023 R Fowzan Alkuraya, King Khaled Eye
Specialist Hospital
NCT01482195
Retinoschisis rAAV2tYF-CB-hRS1 I/II 27 C,A,S 2015–2020 NYR Applied Genetic Technologiesa NCT02416622
AAV-RS1 I/II 100 A,S 2014–2017 R National Eye Institute NCT02317887
Stargardt macular degeneration StarGen I/II 46 C,A,S 2011–2017 R Sanofia NCT01367444
StarGen I/II 28 A,S 2012–2022 R Sanofia NCT01736592
Usher syndrome UshStat I/II 18 A,S 2012–2017 R Sanofia NCT01505062g
UshStat I/II 18 A,S 2013–2022 R Sanofia NCT02065011
A¼ adult; C¼ child; Com¼ completed; N/A¼ not available; NYR¼ not yet open for participant recruitment; ONR¼ ongoing, but not recruiting participants; R¼ recruiting/enrolling by invitation;
S ¼ senior.
aIndustry sponsor.
bNightstaRx AAV2-REP1 product.
cResults published by Seitz et al13 (PubMed ID 25744334) and MacLaren et al14 (PubMed ID: 24439297).
dResults published by Melillo et al15 (PubMed ID: 22812667), Maguire et al7 (PubMed ID: 19854499), and Maguire et al4 (PubMed ID: 18441370).
eResults published by Bainbridge et al11 (PubMed ID: 25938638) and Bainbridge et al2 (PubMed ID: 18441371).
fResults published by Jacobson et al10 (PubMed ID: 25936984), Cideciyan et al16 (PubMed ID: 25537204), and Jacobson et al17 (PubMed ID: 21911650).
gResults published by Zallocchi et al18 (PubMed ID: 24705452).
V
O
L.
1
6
0,
N
O
.
3
4
0
9
C
O
M
M
U
N
IC
A
T
IN
G
T
H
E
P
R
O
M
ISE
FO
R
O
C
U
LA
R
G
EN
E
T
H
ER
A
P
IES
vectors and surgical delivery to ensure that patients
receive an optimal dose for long-lasting effects.12
The LCA trials have paved the way for other retinopa-
thies (Table). Public and private investments now support
companies created to advance clinical development of
ocular gene therapy. Spark Therapeutics has licensed tech-
nologies from the Children’s Hospital of Philadelphia,
including those designed for LCA and choroideremia
(http://www.sparktx.com/). NightstaRx was similarly
launched in the United Kingdom to develop a gene therapy
product for choroideremia (http://www.nightstarx.com/).
Spin-off companies such as these enable scale-up from clin-
ical trials to gene therapies available to patients in the
clinic. However, potential financial conflicts of interest
for researchers conducting clinical trials and involved in
sponsoring companies must be managed carefully. Clinical
trial participants must be informed of any conflicts of inter-
est during consent processes to ensure the integrity of the
research. Lessons may be taken from the early days of
gene therapy clinical trials. Financial conflicts of interest,
along with improper informed consent and protocol viola-
tions, damaged the reputation and progress of the field
following the death of Jesse Gelsinger in a gene therapy
clinical trial at the University of Pennsylvania in 1999.
Against this backdrop, patients and their families are
increasingly likely to request information from clinicians
about emerging therapies. Patients may ask about potential
treatment options or about articles on experimental inter-
ventions that they have retrieved from external sources; pa-
tients may inquire about clinical trials and about the
possibility of enrolling in such trials; and patients may
ask about early or compassionate access programs that are
available in some countries. These programs allow health
care providers to apply for the use of investigational prod-
ucts such as unapproved drugs or devices that are still in
clinical trial or market approval stages. To be eligible for
such access programs, patients must have serious or life-
threatening conditions, have no alternative therapy op-
tions, and have no other product access option (including
clinical trial participation), and the potential benefits of
the product must outweigh the risks. This risk-vs-benefit ra-
tio is difficult to characterize for products that are in early
phases of clinical trials.A COMMUNICATIONS LANDSCAPE OF
PROMISE
COMMUNICATIONS ABOUT CUTTING-EDGE RESEARCH
will not occur in an informational vacuum. When discus-
sing research with patients, clinicians need to be attentive
to patient priorities and concerns but also responsive to
other sources of information. These sources include
news media, patient advocacy organizations, industry, so-
cial media, health and research organization websites, and410 AMERICAN JOURNAL OFother Internet sources, as well as family and friends. Forty
percent of the American public follow health news stories
closely,19 especially those that are personally relevant20;
Internet access to health information is widespread and
growing.21
Media coverage of genetic research, particularly clinical
research, is highly positive, framed as a celebration of prog-
ress in research.22 News articles focus on benefits, while
omitting or downplaying risks, and provide limited back-
ground information for readers to assess the validity or cred-
ibility of the research (including funding sources and
potential conflicts of interest). They accelerate timelines
by presenting preclinical or early-stage research as an
imminent therapy or cure.23 News articles often contextu-
alize research with a human-interest story focused on a
hopeful patient or a heroic researcher.24 Media coverage
of ocular gene therapy clearly follows this pattern.25 It de-
scribes a range of visual outcomes from slowing vision loss
to a cure, even though the latter is clinically infeasible.
This positive coverage of ocular gene therapy generates
high expectations in patient communities. For example, af-
ter the highly publicized successes in early-phase LCA tri-
als, clinical reports documented a trend of LCA patients
and families wishing to access clinical trials.26 Less publi-
cized was the caveat that the initial LCA trials addressed
only 1 of 17 known genetic mutations underlying the dis-
ease, representing only 5% of LCA cases.26
Patient organizations, such as the Foundation Fighting
Blindness (www.ffb.ca) and the Choroideremia Research
Foundation (cureCHM.org), also contribute to the com-
munications landscape. These organizations both fund
innovative research and communicate with patients and
the public about associated risks, benefits, and timelines.
Featured prominently on these sites are current and
planned gene therapy clinical trials. The Foundation
Fighting Blindness provides up-to-date information on
clinical trials and genetic testing resources and maintains
a patient registry as a tool to connect individuals living
with inherited eye diseases to scientists researching those
conditions. The Choroideremia Research Foundation
operates similarly, and has recently adopted the Founda-
tion Fighting Blindness MyRetinaTracker (https://www.
myretinatracker.org), a registry that allows patients to up-
load their genotypic, phenotypic, lifestyle, and other
clinical data to enable de-identified research use. Such
registries are facilitated by advancements in genetic
testing, including next-generation sequencing, that
enable molecular diagnostics.27,28 While access to
genetic testing may be differentially covered by health
care systems and insurance policies,29 if available, molec-
ular diagnostics may improve health-related quality of life
by providing valuable information for reproductive coun-
seling in cases of de novo mutations, information neces-
sary to enroll patients in clinical trials, and empowering
patients with knowledge and the opportunity to actively
drive the research process forward.30,31SEPTEMBER 2015OPHTHALMOLOGY
In summary, patients increasingly access health informa-
tion from print and broadcast media sources and on the
Internet and raise this information during clinical visits.
However, it is challenging for patients to assess the accu-
racy and credibility of such information, and reports on
research into ocular gene therapy and related bio-
therapeutics paint a highly optimistic view of timelines
and expected outcomes. Studies consistently emphasize
the relational nature of care (between patients and their
families and clinicians) and demonstrate better outcomes
if the concerns of patients are met.32 Here we discuss
how clinicians might aid patients and families in navi-
gating the complex web of information and supporting
hope while keeping expectations grounded in current clin-
ical and research realities.CLINICAL COMMUNICATION TOPICS
AND RECOMMENDATIONS
 RESEARCH, NOT TREATMENT: Coverage of novel bio-
therapeutics conflates research with therapy. The very
use of the term ‘‘therapy’’ in a clinical research context im-
plies demonstrated therapeutic effect,1 but cumulative ev-
idence suggests that fewer than 1% of participants derive a
direct benefit from phase I gene therapy clinical trials.33
Media articles use research and treatment terminology
interchangeably,25 confusing research goals and the state
of clinical development.34 This confusion is problematic
in the context of clinical trial enrollment, as hope for ther-
apeutic benefit from early-stage clinical trials exemplifies a
‘‘therapeutic misconception.’’35 Such a misconception may
undermine consent processes in clinical trial enrollment,
which require participants to understand the research
goals.35
In reality, research extends along a developmental con-
tinuum from laboratory research using cell and animal
models to preclinical or enabling research—the goals of
which are to demonstrate safety and the proposed mode
of action of the therapeutic for regulatory clinical trial ap-
plications—through the phases of clinical trials. Rates of
attrition between phases of clinical trials are high. Of inter-
ventions that enter phase 1, only 15% receive market
authorization from a regulatory agency following phase 3
clinical trials; the greatest attrition occurs in phase 236
and is likely worse for more complex biotherapeutics.
Phase I clinical trials are designed to test safety and the
maximum tolerable dose. Though some safety outcome
measures blur with those for efficacy, small phase 1 studies
are inadequately powered to test the latter. For example,
the first clinical study on choroideremia gene transfer
published in The Lancet reported on 6 patients.14 Similarly,
published accounts of the LCA trials reported on 3 partic-
ipants in the New England Journal of Medicine (2008), a
dose-escalation study in 12 participants in The Lancet,7VOL. 160, NO. 3 COMMUNICATING THE PROMISE Fand a follow-up study 3 years after treatment in 5 partici-
pants.37 While preliminary results appear promising, these
are not without the caveats discussed in the introduction.
More definitive evidence of efficacy for LCA gene therapy
will emerge from the phase III trial later this year; peer-
reviewed, published accounts demonstrating efficacy of
ocular gene therapy remain, at present, limited.
Recommendation. When discussing access to an investi-
gational gene therapy product by way of a clinical trial or
otherwise, clinicians should address sources of information,
the goals of different phases of clinical trials, the credibility
of the clinical trial (including the site, sponsor, and
research team), and that clinical trials represent research,
not therapy. Clinicians may point patients and families
to credible sources of information. For example, the Foun-
dation Fighting Blindness website, while acknowledging
patient hopes for a treatment, explicitly states: ‘‘The word
intervention is used instead of the word treatment to
help people remember that the drug and/or surgery that
the participant is receiving is not an established treatment.
A clinical trial is not a treatment it is an experiment.’’38
 PARTICIPATION IN CLINICAL RESEARCH IS NOT RISK
FREE: Media coverage of ocular gene therapy has been
highly positive; like most coverage of genetics,39 it empha-
sizes benefits and provides minimal information on risks.25
While most published accounts of gene therapy have
shown positive safety profiles, some risks are apparent.
General risks for gene therapy, which remain hypothetical
risks for ocular applications, include oncogenic risks from
insertional mutagenesis and a severe immune response.40
Specific risks include surgical complications, loss of
an eye owing to endophthalmitis, loss of remaining
vision,2–4 and a theoretical risk of brain toxicity owing to
integration of the viral vector in the optic nerve.
Reported adverse events include a macular hole,4 foveal
thinning,17 and retinal detachment.14 Other risks to partic-
ipants include associated financial burdens and psycholog-
ical stress. While disclosure of risks is an essential
component of the informed consent process for clinical
trial participation, urgency to access a trial may divert pa-
tient attention from the risks.34
Recommendation. When discussing possible participa-
tion in a clinical trial, clinicians should highlight that po-
tential risks exist. Clinicians may direct patients to
carefully consider and question descriptions of both magni-
tude and likelihood of risks during the process of informed
consent.
 POTENTIAL TREATMENT, NOT CURE: If proven safe and
efficacious, gene therapy may present a treatment but not a
cure for patients who have already experienced vision loss.
While gene therapy may restore the function of dormant
yet viable photoreceptors and thereby improve visual411OR OCULAR GENE THERAPIES
FIGURE 1. Visual outcome perspectives of choroideremia gene
therapy stakeholders and ocular gene therapy media representa-
tions.outcome measures, unlike proposed cell therapies, it is not
regenerative.17 The LCA trials demonstrate that there may
be a therapeutic window for efficacy, with earlier interven-
tion being better, especially if prior to the onset of retinal
degeneration.8 Nevertheless, the media commonly repre-
sent gene therapy as a cure for inherited eye diseases.25
One popular book on LCA gene therapy went so far as to
be titled The Forever Fix.41
Other stakeholder perspectives tend to be more
nuanced. Participants in one choroideremia study antici-
pated outcomes that ranged from no benefit, through slow-
ing or halting vision loss, to a cure for choroideremia
(Figure 1).34 All stakeholder groups acknowledged the pos-
sibility of no benefit. However, although clinicians and
advocacy organizations did not express expectations for a
cure and considered slowing vision loss as a realistic
outcome, patient perspectives ranged from halting vision
loss to a cure. In other words, patients overestimated the
potential benefits of gene therapy research, which repre-
sents a ‘‘therapeutic misestimation.’’35 Such overestimation
of benefit may be ethically tolerable if its probability was
difficult to convey or perceive,35 but in the case of ocular
gene therapy, a cure is highly unlikely. Its long-term effects
are unknown at present.8
Recommendation. It is important for clinicians to clearly
communicate the spectrum of possible visual benefits of
future gene therapies. Gene therapy is not regenerative,
and therefore will not revive cells that have already degen-
erated. Thus, if approved by United States regulators as the
first ocular gene therapy product following phase III clinical
trials, Spark Therapeutics’ gene therapy for LCA will be a
treatment, not a cure. Mounting evidence suggests that
gene therapy may need to be readministered, or adminis-
tered in combination with medications that may still be
in development.12
 TRANSLATIONAL TIMELINES ARE LENGTHY: The road
to the clinic for novel biotherapeutics is long and412 AMERICAN JOURNAL OFchallenging. Even for small-molecule drugs, it takes 10-14
years, with estimated costs in the billions, to move from pre-
clinical studies to market authorization by a regulatory
agency.42 Gene therapy has been hailed as 5 years away
from clinical application since the 1990s,43 andmedia, clini-
cians, and patient advocates contribute to patient confusion
by expressing vague timelines for its arrival in the clinic.25,34
The media often depict the promise of research without
providing context of when the described benefits may be
realized. They widen the gap between patient hopes for an
imminent treatment and the clinical reality of limited ther-
apeutic options for many conditions.44 For example, choroi-
deremia patients were left uncertain about whether gene
therapies would become available within their own thera-
peutic window for visual gain.25Nevertheless, these patients
wished to consider future therapeutic options, such as gene
therapy, when making current disease management deci-
sions. Contextualizing expected times (and uncertainties)
from mutation identification to potential gene therapy clar-
ifies media accounts that make a direct link between discov-
ery of ‘‘blindness-causing genes’’ and treatments.45
The history of LCA gene therapy research is illustrative
of timelines (Figure 2). The RPE65 mutation was identified
in 199746; phase I/II human trials began in 20072 with cur-
rent trials in phase III (NCT00999609). The gene therapy
product may become the first approved in the United
States, aided in part by financial and regulatory incentives
that expedite approval for orphan drugs that treat serious
conditions and fill unmet medical need.47 NightstaRx, for
example, recently announced that it has received orphan
drug status in both the United States and Europe for its
choroideremia gene therapy product (http://www.
nightstarx.com/). While it is a necessary precursor to clin-
ical availability, regulatory approval is not the endpoint.
Novel biotherapies must still be adopted into clinical set-
tings and be paid for by public or private insurers.48 These
therapies are often very expensive and must clear value as-
sessments by cash-strapped health systems and hospitals.49
Recommendation. Patients wish to weigh future thera-
peutic options when making current disease management
decisions. Consequently, clinicians should discuss research
timelines in relation to their patients’ vision loss and prog-
noses. Clinicians can assist patients by providing realistic
timelines and positioning current research within models
of clinical translation. Valuable information includes the
phases of clinical trials and their goals, regulatory ap-
provals, insurance/health system coverage decisions, and
eventual clinical adoption. Such context will assist patients
in assessing the likelihood of a gene therapy within a ther-
apeutically meaningful window for their vision loss.
 CELEBRATING HOPES THAT ARE GROUNDED IN CUR-
RENT CLINICAL REALITIES: The last 20 years have seen
tremendous advances in research for retinopathies
including the identification of over 280 genes and lociSEPTEMBER 2015OPHTHALMOLOGY
FIGURE 2. Translational timeline of gene therapy for Leber congenital amaurosis (LCA).50–52 Colors indicate research groupings.
Red[Maguire/Bennett group: University of Pennsylvania and Children’s Hospital of Philadelphia (CHOP); gene therapy product
licensed by Spark Therapeutics. Blue [ Jacobson/Cideciyan group: University of Pennsylvania. Green [ Bainbridge group:
University College, London.underlying inherited retinal disorders.53 and a shift from
basic science inquiry to targeted preclinical and clinical tri-
als using gene transfer, stem cell, drug, and optogenetic ap-
proaches.54 These developments provide a landscape of
hope, which is rooted in a ‘‘paradox of uncertainty’’55—pos-
itive clinical trials have the potential to transform current
prognoses of vision loss but may equally be a source of anx-
iety or vulnerability. The latter arises because treatments
may not become available within the limited therapeutic
windows of patients.
Reflecting on hope, Ruth McGovern, mother of 2 boys
with adrenoleukodystrophy, an X-linked metabolic disorder
targeted by gene therapy research, stated: ‘‘hope is uplifting
and valuable when all around is uncertain for without hope
the alternative for me would be despair.’’56 Hope both sup-
ports and is supported by disease management. But hope
may also challenge pragmatic efforts to prepare for a prognosis
of vision loss,34 including vocational and assistive technology,
dietary supplementation, and social supports.
Recommendation. These findings necessitate a commu-
nications approach that acknowledges patient hopes
for possible therapeutic interventions, while groundingVOL. 160, NO. 3 COMMUNICATING THE PROMISE Fexpectations in current clinical realities. In other words, clini-
ciansmight employ a ‘‘plan for today, hope for tomorrow’’mes-
sage. Clinicians may employ a wellness-based approach,
emphasizing enhancement in the emotional, psychological,
and spiritual dimensions of quality of life in addition to
hopes for physiological improvements.55CONCLUSION
OCULAR GENE THERAPY CLINICAL TRIALS ARE RAISING
hopes for treating a myriad of hereditary retinopathies. How-
ever, for most diseases, such therapies are many years in the
future. We call for a clinical communications approach that
respects and contextualizes patient hopes within current clin-
ical and research realities. Clinicians should be prepared to
counter overly optimistic messaging, especially that found
in news media and on the Internet, with optimism tempered
by evidence. Such communications will become increasingly
important as novel gene and cell therapies advance through
clinical development and will support the ethical translation
of these fields.413OR OCULAR GENE THERAPIES
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